Overcome the challenges of PMS2 variant calling with Devyser LynchFAP – our new NGS solution
Devyser LynchFAP is the latest addition to Devyser’s expanding hereditary cancer screening...
Please find the terms and conditions for different countries and regions below.
Country | Legal terms |
---|---|
Austria | Terms and conditions |
Benelux | Terms and conditions |
Germany | Terms and conditions |
Switzerland | Terms and conditions |
United Kingdom | Terms and conditions |
Nordics | Terms and conditions |
North America | Terms and conditions |
Distributor sales | Terms and conditions |
France | Terms and conditions |
News | April 16, 2024
Devyser receives MDSAP certification for BrazilNews | Feb 20, 2024
Devyser Diagnostics AB publishes year-end report for January to December 2023News | Feb 06, 2024
Devyser strengthens its management teamDevyser LynchFAP is the latest addition to Devyser’s expanding hereditary cancer screening...
Read More
Devyser is thrilled to announce the launch of two new products, Devyser LynchFAP and Devyser BRCA...
Read More
As a lab manager, you know the importance of streamlining workflows to maximize productivity and...
Read More
Do you know a man who has participated at least once in “Movember”? Every year, thousands of men...
Read More